Sector |
|
Compare with Sector peers |
Industry |
|
Compare with Industry peers |
Website | http://www.jubilantpharmova.com | |
Market Cap | 6,498.67 Cr. | |
Enterprise Value(EV) | 8,411.83 Cr. | 2021-09 |
Financial Indicators | ||
---|---|---|
Earnings per share (EPS) | 35.68 | Trailing Twelve Months Ending 2021-12 |
Price-Earning Ratio (PE) | 11.55 | Trailing Twelve Months Ending 2021-12 |
Industry PE | 29.26 | Trailing Twelve Months Ending 2021-12 |
Book Value / Share | 323.91 | Trailing Twelve Months Ending 2021-12 |
Price to Book Value | 1.27 | Calculated using Price: 412.00 |
Dividend Yield | 1.23 | Period Ending 2021-03 |
No. of Shares Subscribed | 15.93 Cr. | 159,281,139 Shares |
FaceValue | 1 | |
Company Profile | ||
Jubilant Life Sciences (formerly Jubilant Organosys) was incorporated in the year 1978. It’s a public limited company domiciled in India and incorporated under the provisions of Companies Act, 1956. Its shares are listed on BSE Limited and National Stock Exchange of India Limited. The Pharmaceuticals segment, through its wholly-owned subsidiary Jubilant Pharma Limited, is engaged in manufacturing and supply of APIs, solid dosage formulations, radiopharmaceuticals, allergy therapy products and contract manufacturing of sterile injectables and non-sterile products through six USFDA approved manufacturing facilities in the US, Canada and India and a network of various radiopharmacies in the US. The Life Science Ingredients segment is engaged in specialty intermediates, nutritional products and life science chemicals through five manufacturing facilities in India. The drug discovery solutions business is served by Jubilant Biosys and the India branded pharmaceuticals business is an Indian venture with a range of pharmaceutical offerings for the domestic market, focusing primarily on products to treat medical conditions in the field of cardiology and diabetology. Business area of the company Jubilant Life Sciences is an integrated global pharmaceutical and life sciences company engaged in pharmaceuticals, life science ingredients, drug discovery solutions and India branded pharmaceuticals. Business segments
Awards 2012
2013
2014
2015
2016
2017
|
1 Day |
|
+3.04% |
1 Week |
|
+3.43% |
1 Month |
|
-13.76% |
3 Month |
|
-7.27% |
6 Month |
|
-32.50% |
1 Year |
|
-51.40% |
2 Year |
|
-9.97% |
5 Year |
|
-41.54% |
10 Year |
|
+122.64% |
9 years | 2013-03 | 2014-03 | 2015-03 | 2016-03 | 2017-03 | 2018-03 | 2019-03 | 2020-03 | 2021-03 | |
Return on Equity (%) | 7.98 | 5.39 | -1.58 | 14.27 | 17.95 | 16.87 | 12.97 | 17.25 | 15.94 | |
Return on Capital Employed (%) | 10.19 | 7.92 | 5.72 | 12.42 | 14.44 | 15.21 | 13.06 | 15.07 | 16.49 | |
Return on Assets (%) | 2.34 | 1.60 | -0.46 | 4.46 | 6.52 | 6.91 | 5.55 | 7.60 | 7.82 |
Particulars | 10 years | 2013-03 Rs. Cr. | 2014-03 Rs. Cr. | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2021-09* Rs. Cr. |
Shh. Funds | 2,476 | 2,627 | 2,454 | 2,966 | 3,436 | 4,087 | 4,809 | 5,604 | 4,741 | 5,109 | |
Non Curr. Liab. | 3,005 | 2,185 | 4,036 | 3,347 | 3,826 | 3,417 | 4,420 | 4,088 | 2,973 | 3,070 | |
Curr. Liab. | 2,778 | 3,894 | 2,129 | 2,464 | 1,684 | 2,005 | 2,090 | 2,619 | 1,049 | 1,160 | |
Minority Int. | 112 | 158 | -38 | -47 | -52 | 0 | 0 | 0 | |||
Equity & Liab. | 8,371 | 8,864 | 8,619 | 8,740 | 8,899 | 9,457 | 11,319 | 12,310 | 8,763 | 9,338 | |
Non Curr. Assets | 5,810 | 5,936 | 5,904 | 5,864 | 5,951 | 6,267 | 6,734 | 7,272 | 5,811 | 6,077 | |
Curr. Assets | 2,561 | 2,928 | 2,715 | 2,875 | 2,948 | 3,190 | 4,585 | 5,038 | 2,953 | 3,261 | |
Misc. Exp. not W/O | |||||||||||
Total Assets | 8,371 | 8,864 | 8,619 | 8,740 | 8,899 | 9,457 | 11,319 | 12,310 | 8,763 | 9,338 |
Particulars | 10 years | 2013-03 Rs. Cr. | 2014-03 Rs. Cr. | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2021-12 Rs. Cr. TTM |
Net Sales | 5,166 | 5,803 | 5,826 | 5,749 | 5,861 | 7,518 | 9,111 | 9,154 | 8,906 | 6,182 | |
Other Income | 30 | 19 | 42 | 13 | 25 | 40 | 36 | 47 | 30 | 21 | |
Total Income | 5,196 | 5,822 | 5,869 | 5,763 | 5,886 | 7,558 | 9,147 | 9,202 | 8,935 | 6,203 | |
Total Expenditure | -4,098 | -4,782 | -5,125 | -4,502 | -4,516 | -5,999 | -7,372 | -7,207 | -7,014 | -4,899 | |
PBIDT | 1,098 | 1,040 | 744 | 1,260 | 1,370 | 1,558 | 1,775 | 1,995 | 1,921 | 1,305 | |
Interest | -311 | -337 | -368 | -371 | -341 | -284 | -220 | -287 | -247 | -149 | |
Depreciation | -254 | -281 | -288 | -347 | -291 | -415 | -371 | -462 | -452 | -367 | |
Taxation | -152 | -70 | -80 | -155 | -163 | -225 | -327 | -312 | -376 | -254 | |
Exceptional Items | -192 | -214 | -48 | -280 | -35 | -21 | -10 | ||||
PAT | 189 | 138 | -40 | 387 | 575 | 634 | 577 | 898 | 824 | 524 | |
Minority Interest | -36 | -29 | -18 | 5 | 1 | 8 | -3 | 0 | 1 | ||
Share Associate | 11 | 3 | |||||||||
Other Related Items | |||||||||||
Consolidated Net Profit | 153 | 109 | -58 | 392 | 576 | 643 | 574 | 898 | 836 | 568 | |
Adjusted EPS | 10 | 7 | -4 | 25 | 37 | 41 | 36 | 56 | 53 | 36 |
Particulars | 10 years | 2012-03 Rs. Cr. | 2013-03 Rs. Cr. | 2014-03 Rs. Cr. | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. |
Cash Fr. Operatn. | 707 | 970 | 772 | 783 | 1,099 | 1,268 | 1,303 | 1,122 | 1,543 | 1,784 | |
Cash Fr. Inv. | -594 | -500 | -174 | -343 | -313 | -450 | -618 | -1,012 | -327 | -739 | |
Cash Fr. Finan. | -889 | -450 | -414 | -503 | -843 | -686 | -901 | 657 | -1,050 | -1,709 | |
Net Change | -776 | 20 | 183 | -63 | -56 | 132 | -216 | 767 | 166 | -664 | |
Cash & Cash Eqvt | 263 | 280 | 473 | 392 | 339 | 456 | 244 | 1,005 | 1,231 | 502 |
Sat, 21 May 2022
Compliances-Reg.24(A)-Annual Secretarial Compliance Pursuant to the SEBI Circular no. CIR/CFD/CMD1/27/2019 dated February 8 2019 please find enclosed the Annual Secretarial Compliance Report dated May 18 2022 for the financialyear 2021-22. We request you to take the same on record. |
Fri, 20 May 2022
Board Meeting Intimation for Intimation Of Board Meeting - May 27 2022 Jubilant Pharmova Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 27/05/2022 inter alia to consider and approve In terms of Regulation 29 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations 2015 (the Listing Regulations) we wish to inform you that a meeting of the Board of Directors of the Company is scheduled to be held on Friday May 27 2022 to inter-alia consider:1. Audited Standalone and Consolidated Financial Results of the Company for the quarter and year ended March 31 2022; and 2. Recommendation of Dividend for the Financial Year ended March 31 2022.This is for information and record. |
Fri, 20 May 2022
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation Pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations 2015 we wish to inform you that the Company is organising a Conference Call on May 27 2022 after submission of the financial results for the quarter and year ended March 31 2022 to the Stock Exchanges. Details of the Conference Call are attached. This is for information and record. |
Fri, 20 May 2022 |
|
|
|
|
|